Experience with anti-TNF-α therapy for orofacial granulomatosis.

@article{Elliott2011ExperienceWA,
  title={Experience with anti-TNF-α therapy for orofacial granulomatosis.},
  author={Tim R Elliott and Helen Campbell and M. P. Escudier and T W J Poate and Carlo Nunes and M C E Lomer and A Lexi Mentzer and Pritash Patel and Penelope J Shirlaw and Jonathon Brostoff and Stephen J Challacombe and Jeremy David Sanderson},
  journal={Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology},
  year={2011},
  volume={40 1},
  pages={14-9}
}
BACKGROUND Orofacial granulomatosis (OFG) can be challenging to treat and experience with anti-TNF-α therapy is limited. We report our experience with infliximab (IFX) and adalimumab (ADA) for OFG in 14 patients, the largest reported series to date. METHODS A review of patients receiving induction and maintenance IFX for OFG +/- Crohn's disease (CD) for active oral disease failing other therapies was performed. Clinical response defined by global physician assessment, aided by oral disease… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
8 Extracted Citations
0 Extracted References
Similar Papers